Michael H. Davidson
Chief Executive Officer at NewAmsterdam Pharma Company N.V.
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 3 boards, counting each seat separately. Longest: NewAmsterdam Pharma Company N.V., 2 years.
NewAmsterdam Pharma Company N.V.
Director · Chief Executive Officer
Tenax Therapeutics Inc.
Director
BioAge Labs Inc.
Director
Chief executive roles
NewAmsterdam Pharma Company N.V.
· Chief Executive Officer
Since December 2023
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 20, 2024 | NewAmsterdam Pharma Company N.V. | Open-market purchase | +5,000 | $16.27 | $81,350 |
| Aug 8, 2024 | Tenax Therapeutics Inc. | Open-market purchase | +2,500 | — | — |
| Jun 20, 2024 | NewAmsterdam Pharma Company N.V. | Open-market purchase | +5,000 | $17.26 | $86,300 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.